DynPort Vaccine Company (DVC), a Computer Sciences Corporation (CSC) company, has received a follow-on contract to continue supporting the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Valued at up to $90 million, the award is a 10-year Indefinite Delivery/Indefinite Quantity contract to support and conduct Phase 1 clinical trials of infectious disease therapeutics.
Under the agreement, DynPort and its teaming partners, Quintiles, Health Decisions and WCCT Global, will support and manage Phase 1 clinical trial units to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties, which will inform appropriate human dosing regimens.
As the prime contractor, DynPort will manage the overall program and clinical operations, quality assurance and co-development of protocols and concepts. Quintiles, Health Decisions and WCCT Global will provide clinical research and support services for the implementation and conduct of approved clinical trial protocols.
Trials will include therapeutic candidates for a broad range of infectious diseases, and investigational products tested will include those to protect against viral, bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
Under the existing contract with NIAID awarded in 2008, DVC has completed four Phase 1 trials, while continuing to progress on three others. DVC also developed study protocols and clinical trial concepts for NIAID under separate task orders. Adding Health Decisions and WCCT Global, both small businesses, to the new contract increases DVC’s access to Phase 1 units across the United States and provides greater flexibility and efficiencies to NIAID.